Taurolidine and catheter-related bloodstream infection: A systematic review of the literature

Journal of Pediatric Gastroenterology and Nutrition

Volumn 47, Issue 2, 2008, Pages 179-186

  Bradshaw, Joanne H ^a   Puntis, John W L ^b  

^a CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Catheter related bloodstream infection; Central venous catheter; Taurolidine

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CATHETER LOCK SOLUTION; CIPROFLOXACIN; CITRIC ACID; EDETATE CALCIUM DISODIUM; HEPARIN; MINOCYCLINE; NEUTROLIN; RIFAMPICIN; TAUROLIDINE; TAUROLOCK; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; TAURINE; THIADIAZINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BIOFILM; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CATHETER INFECTION; CATHETER OCCLUSION; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DIALYSIS CATHETER; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INSTILLATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBRYOTOXICITY; ENTEROCOCCUS FAECALIS; FUNGAL ENDOCARDITIS; HEART ATRIUM THROMBOSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFECTION RATE; INTRAVENOUS FEEDING; NEUTROPENIA; NONHUMAN; PAIN; PARENTERAL NUTRITION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; THROMBUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CENTRAL VENOUS CATHETERIZATION; EQUIPMENT; EVIDENCE BASED MEDICINE; META ANALYSIS; REVIEW; SEPSIS;

ANTI-INFECTIVE AGENTS; CATHETERIZATION, CENTRAL VENOUS; EQUIPMENT CONTAMINATION; EVIDENCE-BASED MEDICINE; HUMANS; SEPSIS; TAURINE; THIADIAZINES;

EID: 56049122205     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318162c428     Document Type: Article

References (21)

1. Raad I. Intravascular-catheter-related infections. Lancet 1998; 351:893-8.
2. Betjes MGH, van Agteren M. Prevention of dialysis catheter- related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004;19:1546-51.
3. http://www.taurolock.de. Accessed December 2006.
4. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-22.
5. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-8.
6. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, et al. Activities of taurolidine in vitro and in experimental endocarditis. Antimicrob Agents Chemother 2000;44:1720-4.
7. Mermal L, Parenteau S. Efficacy of the Biolink Catheter Lock Solution for Dialock haemodialysis access port and catheters. Poster at International Conference on Nosocomial and Health Associated Infections 2000. Infect Control Hosp Epidemiol 2000;21:86-174.
8. Sherertz RJ, Boger MS, Collins CA, et al. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother 2006;50:1865-8.
9. Simon A, Wieszniewsky G, Bode U. Taurolidine as standard lock solution reduces CVAD-associated Gram-positive infections in pediatric cancer patients [abstract]. Onkologie 2006;29 (Suppl 3): 212.
10. Shah CB, Mittelman MW, Costerton JW, et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002;46:1674-9.
11. Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2004;24:491-5.
12. Johnston DA, Phillips G, Perry M, et al. Taurolin for the prevention of parenteral nutrition related infection: antimicrobial activity and long-term use. Clin Nutr 1993;12:365-8.
13. Phillips B, Ball C, Sackett D et al. Oxford Centre for Evidence-based Medicine levels of evidence. May 2001. Centre for Evidence-Based Medicine Web site. http://www.cebm.net. Accessed May 30, 2008.
14. Droste JC, Jeraj HA, MacDonald A, et al. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003;51:849-55.
15. Jurewitsch B, Lee T, Park J, et al. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infection. JPEN J Parenter Enteral Nutr 1998;22:242- 4.
16. Sodemann K, Polaschegg HD, Feldmer B. Two years' experience with Dialock and CLS (a new antimicrobial lock solution). Blood Purif 2001;19:251-4.
17. AllonM.Catheter Lock Solution for prophylaxisofdialysiscatheter- related bacteremia: a pilot study. American Society of Nephrology Conference 2002 [abstract]. J Am Soc Nephrol 2002;13:1A-862A.
18. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Inf Dis 2003;36:1539- 44.
19. Jurewitsch B, Jeejeebhoy KN. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections. Clin Nutr 2005;24:462-5.
20. Vernon MA, Goddard J. The targeted use of Taurolock in reduction of episodes of line sepsis in the "high risk" haemodialysis population [abstract]. Scott Med J 2006;50:54.
21. Geron R, Tanchilevski O, Kristal B. Catheter lock solution- Taurolock for prevention of catheter-related bacteremia in hemo-dialysis patients [in Hebrew]. Harefuah 2006;145:881-4.